Todd Wider

Boxer Capital LLC (Boxer Capital) is a venture capital subsidiary of Tavistock Group, Inc. founded in 2005 by Chris Fuglesang and Aaron I. Davis. The firm is headquartered in San Diego, California.

Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY.

MorphImmune, Inc. is a biotechnology company that specializes in developing targeted oncology therapeutics. MorphImmune is based in West Lafayette, IN and has been led by CEO Clay B. Siegall since 2023. The company's proprietary targeted effector platform delivers payloads to diseased cells, reducing toxicity and increasing efficacy of known effector molecules. The company was founded on the research of Philip S. Low, Ph.D., the Presidential Scholar for Drug Discovery and Ralph C. Corley Distinguished Professor of Chemistry at Purdue University.

Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021.

Gennao Bio, Inc. is a privately-held genetic medicines company that is developing first-in-class, non-viral, targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (gmab) platform technology. The company is based in Pennington, NJ. The company's gmab technology uses a novel, cell-penetrating antibody to non-covalently bind to, and deliver therapeutic levels of a wide variety of nucleic acid payloads, to select cells. Gennao Bio is initially focusing on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases. The company's non-viral delivery platform offers significant advantages over traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and dose optimization, and can be easily and affordably manufactured. The company was founded in 2020 by Bruce Turner, Elias Quijano, Peter M. Glazer, Stephen P. Squinto. Christopher M. Duke has been the CEO of the company since 2021.